Assyro AI

Orange Book product · Brand (NDA)

QBRELIS

LISINOPRIL

Brand (NDA)NDA 208401RX AZURITY
View LISINOPRIL familyOpen on FDA Orange Book

At a glance

Jul 29, 2016

Approved

Brand (NDA)

Application

Not listed

TE code

32

Listed patents

Key dates

  1. Approval

    FDA approval date of this drug product.

    Jul 29, 2016

    10 yr ago

  2. Today

  3. Patent 10039800 expires

    Listed method-of-use patent (U-8) expiration.

    Nov 06, 2035

    in 9 yr 6 mo

  4. Patent 10039800 expires

    Listed method-of-use patent (U-1864) expiration.

    Nov 06, 2035

    in 9 yr 6 mo

  5. Patent 10039800 expires

    Listed method-of-use patent (U-1991) expiration.

    Nov 06, 2035

    in 9 yr 6 mo

  6. Patent 10039800 expires

    Listed method-of-use patent (U-71) expiration.

    Nov 06, 2035

    in 9 yr 6 mo

  7. Patent 10039800 expires

    Listed method-of-use patent (U-1723) expiration.

    Nov 06, 2035

    in 9 yr 6 mo

  8. Patent 10039800 expires

    Listed method-of-use patent (U-3) expiration.

    Nov 06, 2035

    in 9 yr 6 mo

  9. Patent 10039800 expires

    Listed method-of-use patent (U-185) expiration.

    Nov 06, 2035

    in 9 yr 6 mo

  10. Patent 10265370 expires

    Listed drug product patent expiration.

    Nov 06, 2035

    in 9 yr 6 mo

  11. Patent 10406199 expires

    Listed method-of-use patent (U-1864) expiration.

    Nov 06, 2035

    in 9 yr 6 mo

  12. Patent 10406199 expires

    Listed method-of-use patent (U-185) expiration.

    Nov 06, 2035

    in 9 yr 6 mo

  13. Patent 10406199 expires

    Listed method-of-use patent (U-1723) expiration.

    Nov 06, 2035

    in 9 yr 6 mo

  14. Patent 10406199 expires

    Listed method-of-use patent (U-71) expiration.

    Nov 06, 2035

    in 9 yr 6 mo

  15. Patent 10406199 expires

    Listed method-of-use patent (U-1991) expiration.

    Nov 06, 2035

    in 9 yr 6 mo

  16. Patent 10406199 expires

    Listed method-of-use patent (U-3) expiration.

    Nov 06, 2035

    in 9 yr 6 mo

  17. Patent 10406199 expires

    Listed method-of-use patent (U-8) expiration.

    Nov 06, 2035

    in 9 yr 6 mo

  18. Patent 10940177 expires

    Listed drug product patent expiration.

    Nov 06, 2035

    in 9 yr 6 mo

  19. Patent 11179434 expires

    Listed drug product patent expiration.

    Nov 06, 2035

    in 9 yr 6 mo

  20. Patent 11771733 expires

    Listed drug product patent expiration.

    Nov 06, 2035

    in 9 yr 6 mo

  21. Patent 12128083 expires

    Listed drug product patent expiration.

    Nov 06, 2035

    in 9 yr 6 mo

  22. Patent 12186360 expires

    Listed drug product patent expiration.

    Nov 06, 2035

    in 9 yr 6 mo

  23. Patent 12433931 expires

    Listed method-of-use patent (U-1723) expiration.

    Nov 06, 2035

    in 9 yr 6 mo

  24. Patent 12433931 expires

    Listed method-of-use patent (U-1864) expiration.

    Nov 06, 2035

    in 9 yr 6 mo

  25. Patent 12433931 expires

    Listed method-of-use patent (U-3) expiration.

    Nov 06, 2035

    in 9 yr 6 mo

  26. Patent 9463183 expires

    Listed drug product patent expiration.

    Nov 06, 2035

    in 9 yr 6 mo

  27. Patent 9616096 expires

    Listed method-of-use patent (U-3) expiration.

    Nov 06, 2035

    in 9 yr 6 mo

  28. Patent 9616096 expires

    Listed method-of-use patent (U-185) expiration.

    Nov 06, 2035

    in 9 yr 6 mo

  29. Patent 9616096 expires

    Listed method-of-use patent (U-1723) expiration.

    Nov 06, 2035

    in 9 yr 6 mo

  30. Patent 9616096 expires

    Listed method-of-use patent (U-1864) expiration.

    Nov 06, 2035

    in 9 yr 6 mo

  31. Patent 9616096 expires

    Listed method-of-use patent (U-1991) expiration.

    Nov 06, 2035

    in 9 yr 6 mo

  32. Patent 9616096 expires

    Listed method-of-use patent (U-8) expiration.

    Nov 06, 2035

    in 9 yr 6 mo

  33. Patent 9616096 expires

    Listed method-of-use patent (U-71) expiration.

    Nov 06, 2035

    in 9 yr 6 mo

  34. Patent 9814751 expires

    Listed drug product patent expiration.

    Nov 06, 2035

    in 9 yr 6 mo

Pharmaceutical detail

Active ingredient

LISINOPRIL

Strength

1MG/ML

Dosage form

SOLUTION

Route

ORAL

TE code

Not listed

Application

NDA 208401

Product number

001

Marketing status

RX

Reference listed drug (RLD)

Yes

Reference standard (RS)

Yes

Active-ingredient family

View full family

This is a reference-listed drug (RLD) — the basis for generic (ANDA) applications. Other products sharing this ingredient are listed below.

Listed patents (32)

Patents listed in the FDA Orange Book for this product, with expiration date and patent type.
PatentExpiresInType
10039800Nov 06, 2035in 9 yr 6 mo
U-8
10039800Nov 06, 2035in 9 yr 6 mo
U-1864
10039800Nov 06, 2035in 9 yr 6 mo
U-1991
10039800Nov 06, 2035in 9 yr 6 mo
U-71
10039800Nov 06, 2035in 9 yr 6 mo
U-1723
10039800Nov 06, 2035in 9 yr 6 mo
U-3
10039800Nov 06, 2035in 9 yr 6 mo
U-185
10265370Nov 06, 2035in 9 yr 6 mo
Product
10406199Nov 06, 2035in 9 yr 6 mo
U-1864
10406199Nov 06, 2035in 9 yr 6 mo
U-185
10406199Nov 06, 2035in 9 yr 6 mo
U-1723
10406199Nov 06, 2035in 9 yr 6 mo
U-71
10406199Nov 06, 2035in 9 yr 6 mo
U-1991
10406199Nov 06, 2035in 9 yr 6 mo
U-3
10406199Nov 06, 2035in 9 yr 6 mo
U-8
10940177Nov 06, 2035in 9 yr 6 mo
Product
11179434Nov 06, 2035in 9 yr 6 mo
Product
11771733Nov 06, 2035in 9 yr 6 mo
Product
12128083Nov 06, 2035in 9 yr 6 mo
Product
12186360Nov 06, 2035in 9 yr 6 mo
Product
12433931Nov 06, 2035in 9 yr 6 mo
U-1723
12433931Nov 06, 2035in 9 yr 6 mo
U-1864
12433931Nov 06, 2035in 9 yr 6 mo
U-3
9463183Nov 06, 2035in 9 yr 6 mo
Product
9616096Nov 06, 2035in 9 yr 6 mo
U-3
9616096Nov 06, 2035in 9 yr 6 mo
U-185
9616096Nov 06, 2035in 9 yr 6 mo
U-1723
9616096Nov 06, 2035in 9 yr 6 mo
U-1864
9616096Nov 06, 2035in 9 yr 6 mo
U-1991
9616096Nov 06, 2035in 9 yr 6 mo
U-8
9616096Nov 06, 2035in 9 yr 6 mo
U-71
9814751Nov 06, 2035in 9 yr 6 mo
Product
Agent CTA Background

Your Next Submission Could Take 6+ Fewer Weeks and Cost $250K Less.

Book a Demo